Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences RNA-Seq, Digital PCR, and Liquid Biopsies: Capturing Value from Circulating Biomarkers

Xandra Breakefield's Biography

Xandra Breakefield, Professor, Mass General Hospital (MGH)/Harvard Medical School

Xandra Breakefield, Ph.D. is a basic scientist with a strong background in molecular genetics and neuroscience. She focuses her research efforts on: gene therapy for neurologic diseases; and elucidation of the role of extracellular vesicles (EVs) released from cancer cells in tumor progression. She led early studies demonstrating mutant RNA in serum EVs from glioblastoma patients as biomarkers. She did her undergraduate work at Wilson College and her graduate work in Microbial Genetics at Georgetown University. She was a Postdoctoral Fellow with Nobel Prize winner, Dr. Marshall Nirenberg at the NIH. She is currently Professor of Neurology in the Neuroscience Program at Harvard Medical School and Geneticist in the Neurology and Radiology Services at Massachusetts General Hospital.

Professor Breakefield has received a number of awards for her work, including a McKnight Foundation Neuroscience Development Award, two Javits Neuroscience Investigator Awards, the Society for Neuroscience Mika Salpeter Lifetime Achievement Award, and the Harvard Medical School William Silen Lifetime Achievement Mentoring Award. She is a member of the National Academy of Arts and Sciences and past president of the American Society of Gene and Cell Therapy.

Xandra Breakefield Image

New Dimensions of Extracellular Vesicles – Cell Biopsies and Therapeutic Vehicles

Monday, 21 March 2016 at 10:00

Add to Calendar ▼2016-03-21 10:00:002016-03-21 11:00:00Europe/LondonNew Dimensions of Extracellular Vesicles – Cell Biopsies and Therapeutic

The contributions of EVs to medicine continues to expand. These vesicles are virtual biopsies of living cells in the body that report on their dynamic physiology through an array of proteins, DNA and RNA.  This array is unique to EVs and accessible through biofluids, with profiles informative for different disease states and response to therapy. These vesicles can also be used as stealth vehicles to deliver bioactive agents, including drugs and genes. Their innate stability in vivo, robust loading capacity and ability to achieve efficient delivery to different tissues expands therapeutic modalities.

Add to Calendar ▼2016-03-21 00:00:002016-03-22 00:00:00Europe/LondonRNA-Seq, Digital PCR, and Liquid Biopsies: Capturing Value from Circulating